Desonide label

Desonide

Desonide Recall

Get an alert when a recall is issued.

Side Effects & Adverse Reactions

Warnings

  • for external use only-hands.
  • keep out of eyes. avoid contact with broken skin.
  • stop use and ask a Doctor if irritation or redness develops.
  • do not inhale or ingest. if swallowed, get medical help or contact a poison control center right away.

FDA Safety Alerts

There are currently no FDA safety alerts available for this drug.

Manufacturer Warnings

There is currently no manufacturer warning information available for this drug.

FDA Labeling Changes

There are currently no FDA labeling changes available for this drug.

Uses

Minions

Berry Scented Hand Sanitizer

2 FL OZ (59 mL)

History

There is currently no drug history available for this drug.

Other Information

There are no additional details available for this product.

Desonide Manufacturers

  • Owen Laboratories, Inc.
    Desonide | Foshan Jinxiong Technology Co ., Ltd.
    No Recall

    Desonide | Foshan Jinxiong Technology Co ., Ltd.

    Desonide | Foshan Jinxiong Technology Co ., Ltd.

    Directions

    rub a dime sized drop into hands. for children under 6 use under adult supervision.
  • Desonide | Rebel Distributors Corp
    No Recall

    Desonide | Rebel Distributors Corp

    Desonide | Rebel Distributors Corp

    Desonide cream or ointment should be applied to the affected areas as a thin film two or three times daily depending on the severity of the condition.

    As with other corticosteroids, therapy should be discontinued when control is achieved. If no improvement is seen within 2 weeks, reassessment of diagnosis may be necessary.

    Desonide cream and ointment should not be used with occlusive dressings.

  • Physicians Total Care, Inc.
    Desonide | Physicians Total Care, Inc.
    No Recall

    Desonide | Physicians Total Care, Inc.

    Desonide | Physicians Total Care, Inc.

    Desonide Cream, 0.05% should be applied to the affected area as a thin film two to four times daily depending on the severity of the condition.

    As with other corticosteroids, therapy should be discontinued when control is achieved. If no improvement is seen within two weeks, reassessment of diagnosis may be necessary.

    Desonide Cream, 0.05% should not be used with occlusive dressings.

  • Desonide | Rebel Distributors Corp
    No Recall

    Desonide | Rebel Distributors Corp

    Desonide | Rebel Distributors Corp

    Desonide Cream, 0.05% should be applied to the affected area as a thin film two to four times daily depending on the severity of the condition.

    As with other corticosteroids, therapy should be discontinued when control is achieved. If no improvement is seen within two weeks, reassessment of diagnosis may be necessary.

    Desonide Cream, 0.05% should not be used with occlusive dressings.

  • Perrigo New York Inc
    Desonide | Mylan Pharmaceuticals Inc.
    No Recall

    Desonide | Mylan Pharmaceuticals Inc.

    Desonide | Mylan Pharmaceuticals Inc.
    2.1 Dosing Information

    The recommended dose of sumatriptan tablets is 25 mg, 50 mg, or 100 mg. Doses of 50 mg and 100 mg may provide a greater effect than the 25 mg dose, but doses of 100 mg may not provide a greater effect than the 50 mg dose. Higher doses may have a greater risk of adverse reactions [see Clinical Studies (14)].

    If the migraine has not resolved by 2 hours after taking sumatriptan tablets, or returns after a transient improvement, a second dose may be administered at least 2 hours after the first dose. The maximum daily dose is 200 mg in a 24 hour period.

    Use After Sumatriptan Succinate Injection

    If the migraine returns following an initial treatment with sumatriptan succinate injection, additional single sumatriptan tablets (up to 100 mg/day) may be given with an interval of at least 2 hours between tablet doses.

    The safety of treating an average of more than four headaches in a 30 day period has not been established.

    2.2 Dosing in Patients With Hepatic Impairment

    If treatment is deemed advisable in the presence of mild to moderate hepatic impairment, the maximum single dose should not exceed 50 mg [see Use in Specific Populations (8.6) and Clinical Pharmacology (12.3)].

  • Desonide | Actavis Mid Atlantic Llc
    No Recall

    Desonide | Actavis Mid Atlantic Llc

    Desonide | Actavis Mid Atlantic Llc

    Desonide Cream or Lotion should be applied to the affected areas as a thin film two or three times daily depending on the severity of the  condition. SHAKE LOTION WELL BEFORE USING. As with other corticosteroids, therapy should be discontinued when control is achieved. If no improvement is seen within 2 weeks, reassessment of diagnosis may be necessary. Desonide Cream and Lotion should not be used with occlusive dressings.

  • Taro Pharmaceuticals U.s.a., Inc.
    Desonide | Taro Pharmaceuticals U.s.a., Inc.
    No Recall

    Desonide | Taro Pharmaceuticals U.s.a., Inc.

    Desonide | Taro Pharmaceuticals U.s.a., Inc.

    Desonide cream or ointment should be applied to the affected areas as a thin film two or four times daily depending on the severity of the condition.

    As with other corticosteroids, therapy should be discontinued when control is achieved. If no improvement is seen within two weeks, reassessment of diagnosis may be necessary.

    Desonide cream and ointment should not be used with occlusive dressings.